Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials
Breast cancer is one of the leading causes of cancer-related deaths in women. Regardless of prognosis, all women with breast cancer are at risk for early recurrence. Nearly 50% of early recurrences occur within 5 years of surgery, and they peak at 2 years after surgery in women treated with adjuvant...
Saved in:
Published in | Cancer and metastasis reviews Vol. 29; no. 4; pp. 581 - 594 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
Boston
Springer US
01.12.2010
Springer Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Breast cancer is one of the leading causes of cancer-related deaths in women. Regardless of prognosis, all women with breast cancer are at risk for early recurrence. Nearly 50% of early recurrences occur within 5 years of surgery, and they peak at 2 years after surgery in women treated with adjuvant tamoxifen. Most early recurrences are distant metastases, which strongly correlate with increased mortality. Treatments that mitigate the risk of early distant metastases (DM) are, therefore, likely to improve overall survival in women with early breast cancer (EBC). Aromatase inhibitors (AIs)—anastrozole, letrozole, and exemestane—have been investigated as alternatives to tamoxifen for adjuvant treatment of hormone receptor-positive (HR+) EBC in postmenopausal women (PMW). AIs are better at minimizing risk of early relapse compared with tamoxifen. However, it is not clear if preferential use of AIs over tamoxifen will benefit all PMW with HR+ EBC. The ability to subtype HR+ breast cancer on the basis of biomarkers predictive of response to AIs and tamoxifen would likely be key to determining the most beneficial hormonal treatment within patient subpopulations, but this process requires thorough investigation. Until then, adjuvant therapies that provide the greatest reduction in risk of DM should be considered for all PMW with HR+ EBC. This article reviews the clinical trials of AI adjuvant therapies for hormone-sensitive breast cancer, particularly in the context of how they compare with tamoxifen in minimizing the risk of relapse, occurrence of DM, and breast cancer-related deaths. |
---|---|
AbstractList | Breast cancer is one of the leading causes of cancer-related deaths in women. Regardless of prognosis, all women with breast cancer are at risk for early recurrence. Nearly 50% of early recurrences occur within 5 years of surgery, and they peak at 2 years after surgery in women treated with adjuvant tamoxifen. Most early recurrences are distant metastases, which strongly correlate with increased mortality. Treatments that mitigate the risk of early distant metastases (DM) are, therefore, likely to improve overall survival in women with early breast cancer (EBC). Aromatase inhibitors (AIs)--anastrozole, letrozole, and exemestane-have been investigated as alternatives to tamoxifen for adjuvant treatment of hormone receptor-positive (HR+) EBC in postmenopausal women (PMW). AIs are better at minimizing risk of early relapse compared with tamoxifen. However, it is not clear if preferential use of AIs over tamoxifen will benefit all PMW with HR+ EBC. The ability to subtype HR+ breast cancer on the basis of biomarkers predictive of response to AIs and tamoxifen would likely be key to determining the most beneficial hormonal treatment within patient subpopulations, but this process requires thorough investigation. Until then, adjuvant therapies that provide the greatest reduction in risk of DM should be considered for all PMW with HR+ EBC. This article reviews the clinical trials of AI adjuvant therapies for hormone-sensitive breast cancer, particularly in the context of how they compare with tamoxifen in minimizing the risk of relapse, occurrence of DM, and breast cancer-related deaths. Breast cancer is one of the leading causes of cancer-related deaths in women. Regardless of prognosis, all women with breast cancer are at risk for early recurrence. Nearly 50% of early recurrences occur within 5 years of surgery, and they peak at 2 years after surgery in women treated with adjuvant tamoxifen. Most early recurrences are distant metastases, which strongly correlate with increased mortality. Treatments that mitigate the risk of early distant metastases (DM) are, therefore, likely to improve overall survival in women with early breast cancer (EBC). Aromatase inhibitors (AIs)—anastrozole, letrozole, and exemestane—have been investigated as alternatives to tamoxifen for adjuvant treatment of hormone receptor-positive (HR+) EBC in postmenopausal women (PMW). AIs are better at minimizing risk of early relapse compared with tamoxifen. However, it is not clear if preferential use of AIs over tamoxifen will benefit all PMW with HR+ EBC. The ability to subtype HR+ breast cancer on the basis of biomarkers predictive of response to AIs and tamoxifen would likely be key to determining the most beneficial hormonal treatment within patient subpopulations, but this process requires thorough investigation. Until then, adjuvant therapies that provide the greatest reduction in risk of DM should be considered for all PMW with HR+ EBC. This article reviews the clinical trials of AI adjuvant therapies for hormone-sensitive breast cancer, particularly in the context of how they compare with tamoxifen in minimizing the risk of relapse, occurrence of DM, and breast cancer-related deaths. Breast cancer is one of the leading causes of cancer-related deaths in women. Regardless of prognosis, all women with breast cancer are at risk for early recurrence. Nearly 50% of early recurrences occur within 5 years of surgery, and they peak at 2 years after surgery in women treated with adjuvant tamoxifen. Most early recurrences are distant metastases, which strongly correlate with increased mortality. Treatments that mitigate the risk of early distant metastases (DM) are, therefore, likely to improve overall survival in women with early breast cancer (EBC). Aromatase inhibitors (AIs)--anastrozole, letrozole, and exemestane--have been investigated as alternatives to tamoxifen for adjuvant treatment of hormone receptor-positive (HR+) EBC in postmenopausal women (PMW). AIs are better at minimizing risk of early relapse compared with tamoxifen. However, it is not clear if preferential use of AIs over tamoxifen will benefit all PMW with HR+ EBC. The ability to subtype HR+ breast cancer on the basis of biomarkers predictive of response to AIs and tamoxifen would likely be key to determining the most beneficial hormonal treatment within patient subpopulations, but this process requires thorough investigation. Until then, adjuvant therapies that provide the greatest reduction in risk of DM should be considered for all PMW with HR+ EBC. This article reviews the clinical trials of AI adjuvant therapies for hormone-sensitive breast cancer, particularly in the context of how they compare with tamoxifen in minimizing the risk of relapse, occurrence of DM, and breast cancer-related deaths.[PUBLICATION ABSTRACT] |
Audience | Academic |
Author | Markopoulos, Christos J. |
Author_xml | – sequence: 1 givenname: Christos J. surname: Markopoulos fullname: Markopoulos, Christos J. email: cmarkop@hol.gr, cmbreast@yahoo.gr organization: Athens University Medical School |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23366644$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20830503$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kstu1DAUhiNURC_wAGyQBUKwSfEltpMukEYVl0pFbGBtOZ7jqavEntrJMOUReGoczbTTQYCysJTz_f85Pv6PiwMfPBTFc4JPCcbyXSKYc15igsuGVnW5flQcES5ZKSljB8URJkKWUvDmsDhO6RpnDZPNk-KQ4pphjtlR8euL8653P51fINCxu0UROr1MgLSfo16v74pDBD304AcUxsGEHhJyHl2F2OeZygQ-ucGtAC1DmrCw1GPSHWqzLA3IaG8gniGw1hltpi4rBz9QsGh2kb2d7tLT4rHNBzzbnifF948fvp1_Li-_fro4n12WRlA-lKBx27TStC01vGorTCpKWm5EXQvgmjMphCVQVQZawFYbSc2cE2J4zZrGWnZSvN_4Lse2h7nJd4q6U8voeh1vVdBO7Ve8u1KLsFK0EVQ2PBu82RrEcDNCGlTvkoGu0x7CmJQUmDKau2Xy7X_J_Ip1TZuak4y-_AO9DmP0eRGqxrJimPCp86sNtNAdKOdtyAOayVPNJMnzVbISO6s9yizdjXoInf4Fyt8cemfym1qX_--5ko3AxJBSBHu_MYKni0i1iaPKcVRTHNU6a148XPW94i5_GXi9BXQyurMx58SlHceYEKKqMkc3XMolv4C4286_u_8Gs0v7PQ |
CODEN | CMRED4 |
CitedBy_id | crossref_primary_10_1155_2012_760965 crossref_primary_10_1186_s13058_016_0713_5 crossref_primary_10_1371_journal_pone_0026100 crossref_primary_10_3389_fendo_2022_824362 crossref_primary_10_1038_s41416_018_0158_y crossref_primary_10_1016_j_mce_2016_08_011 crossref_primary_10_1007_s00432_012_1233_z crossref_primary_10_2217_fon_2022_0819 crossref_primary_10_2196_resprot_6519 crossref_primary_10_1186_bcr3191 crossref_primary_10_1016_j_jhazmat_2020_122869 |
Cites_doi | 10.1200/JCO.1996.14.10.2738 10.1093/jnci/93.9.684 10.1016/j.molonc.2007.10.004 10.1056/NEJMoa052258 10.1245/s10434-009-0334-7 10.1158/0008-5472.SABCS-09-16 10.1186/1471-2164-7-278 10.1158/1078-0432.CCR-07-5221 10.1158/0008-5472.SABCS-09-4081 10.1016/S0140-6736(05)66544-0 10.1016/S0140-6736(04)17666-6 10.1093/annonc/mdm271 10.1200/JCO.2005.04.120 10.1200/JCO.2007.13.9279 10.1016/S0960-9776(08)70003-1 10.1002/cncr.22667 10.1007/s10549-006-9428-0 10.1186/bcr2320 10.1056/NEJMoa040331 10.1016/S0140-6736(05)67059-6 10.1016/S1359-6349(09)72025-7 10.1016/S0140-6736(07)60200-1 10.1200/JCO.2007.11.6798 10.1185/030079906X120940 10.1200/JCO.2009.23.1274 10.1080/02841860601034834 10.1001/jama.2009.1420 10.1093/annonc/mdm263 10.1200/JCO.2005.04.7985 10.1158/0008-5472.SABCS-09-12 10.1200/JCO.2006.08.8617 10.1093/jnci/djm246 10.1016/j.ctrv.2007.07.014 10.1158/0008-5472.SABCS-09-13 10.1007/s10549-008-0291-z 10.1056/NEJMra0801289 10.3816/CBC.2006.n.051 10.1111/j.0006-341X.2000.00779.x 10.1002/cncr.10572 10.1016/S1470-2045(07)70385-6 10.1016/j.jsbmb.2007.09.017 10.1200/JCO.2006.08.8054 10.1093/annonc/mdm001 10.1056/NEJMoa041588 10.1016/S0140-6736(02)09088-8 10.1093/jnci/dji250 10.1093/annonc/mdl334 10.1056/NEJMoa032312 10.1093/annonc/mdp322 10.1200/JCO.2007.14.0228 10.1586/14737140.6.10.1355 10.1016/S1470-2045(06)70948-2 |
ContentType | Journal Article |
Copyright | The Author(s) 2010 2015 INIST-CNRS COPYRIGHT 2010 Springer Springer Science+Business Media, LLC 2010 |
Copyright_xml | – notice: The Author(s) 2010 – notice: 2015 INIST-CNRS – notice: COPYRIGHT 2010 Springer – notice: Springer Science+Business Media, LLC 2010 |
DBID | C6C IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK 8FQ 8FV ABUWG AFKRA BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P M3G PQEST PQQKQ PQUKI Q9U 7X8 5PM |
DOI | 10.1007/s10555-010-9248-x |
DatabaseName | Springer Nature OA Free Journals Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Canadian Business & Current Affairs Database Canadian Business & Current Affairs Database (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) CBCA Reference & Current Events ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Oncogenes and Growth Factors Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Pharma Collection ProQuest Central CBCA Complete (Alumni Edition) Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts CBCA Complete ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Central Basic ProQuest One Academic Eastern Edition CBCA Reference & Current Events ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Oncogenes and Growth Factors Abstracts Oncogenes and Growth Factors Abstracts |
Database_xml | – sequence: 1 dbid: C6C name: SpringerOpen(OpenAccess) url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1573-7233 |
EndPage | 594 |
ExternalDocumentID | 2192510401 A712964746 10_1007_s10555_010_9248_x 20830503 23366644 |
Genre | Journal Article Review |
GroupedDBID | --- -4W -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 1SB 2.D 203 28- 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3SX 3V. 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67Z 6J9 6NX 78A 7X7 88E 8AO 8C1 8FI 8FJ 8FQ 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJJC AAJKR AANXM AANZL AAPBV AARHV AARTL AATNV AATVU AAUYE AAWCG AAYFA AAYIU AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABELW ABFGW ABFTV ABHLI ABHQN ABJNI ABJOX ABKAS ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFO ACGFS ACHSB ACHVE ACHXU ACIGE ACIPQ ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACREN ACTTH ACVWB ACWMK ADBBV ADHHG ADHIR ADIMF ADINQ ADKNI ADKPE ADMDM ADOAH ADOXG ADRFC ADTPH ADURQ ADYFF ADYOE ADYPR ADZKW AEBTG AEEQQ AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFEXP AFKRA AFLOW AFNRJ AFQWF AFRAH AFWTZ AFYQB AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG AOSHJ ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BVXVI C6C CAG CCPQU COF CSCUP DDRTE DL5 DNIVK DPUIP DU5 DWQXO EBD EBLON EBS EIOEI EJD EMOBN EN4 EPAXT ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO ICQ IH2 IHE IJ- IKXTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAK LLZTM M1P M3G M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI RNS ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S37 S3B SAP SBY SCLPG SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WH7 WJK WK6 WK8 YLTOR Z45 Z7U Z82 Z87 Z8O Z8V Z91 ZGI ZMTXR ZOVNA ~EX H13 IQODW AACDK AAEOY AAJBT AAQLM AASML AAYZH ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU ALIPV CGR CUY CVF ECM EIF ITC NPM AAYXX ABQSL CITATION 7TO 7XB 8FK H94 K9. PQEST PQUKI Q9U 7X8 5PM |
ID | FETCH-LOGICAL-c625t-ea0b9b7cbb2c54b401421b5c6886e5a53766f1e44cebe0fac72cd511c58399ff3 |
IEDL.DBID | C6C |
ISSN | 0167-7659 |
IngestDate | Tue Sep 17 21:26:40 EDT 2024 Fri Dec 06 00:20:20 EST 2024 Fri Oct 25 09:22:23 EDT 2024 Tue Nov 19 06:34:28 EST 2024 Tue Nov 19 21:06:46 EST 2024 Tue Dec 12 21:20:32 EST 2023 Tue Nov 12 23:17:53 EST 2024 Fri Dec 06 05:43:14 EST 2024 Sat Nov 02 12:09:17 EDT 2024 Sun Oct 22 16:04:07 EDT 2023 Sat Dec 16 12:02:11 EST 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Distant metastasis Exemestane Tamoxifen Anastrozole Letrozole Aromatase inhibitors Steroid Antineoplastic agent Relapse Breast disease Prognosis Azole derivatives Antiestrogen Early stage Antihormone Estrogen synthase Metastasis Selective estrogen receptor modulator Cancerology Postmenopause Clinical trial Non steroid compound Hormone Aromatase inhibitor Enzyme Treatment efficiency Enzyme inhibitor Breast cancer Malignant tumor Androstane derivatives Tamoxifene Mammary gland diseases Triazole derivatives Bibliographic review Cancer |
Language | English |
License | CC BY 4.0 This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c625t-ea0b9b7cbb2c54b401421b5c6886e5a53766f1e44cebe0fac72cd511c58399ff3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Feature-3 ObjectType-Review-1 |
OpenAccessLink | https://doi.org/10.1007/s10555-010-9248-x |
PMID | 20830503 |
PQID | 807430155 |
PQPubID | 36268 |
PageCount | 14 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2962795 proquest_miscellaneous_760232839 proquest_miscellaneous_1008829851 proquest_journals_807430155 gale_infotracmisc_A712964746 gale_infotraccpiq_712964746 gale_infotracacademiconefile_A712964746 crossref_primary_10_1007_s10555_010_9248_x pubmed_primary_20830503 pascalfrancis_primary_23366644 springer_journals_10_1007_s10555_010_9248_x |
PublicationCentury | 2000 |
PublicationDate | 2010-12-01 |
PublicationDateYYYYMMDD | 2010-12-01 |
PublicationDate_xml | – month: 12 year: 2010 text: 2010-12-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Boston |
PublicationPlace_xml | – name: Boston – name: Heidelberg – name: Netherlands – name: Dordrecht |
PublicationTitle | Cancer and metastasis reviews |
PublicationTitleAbbrev | Cancer Metastasis Rev |
PublicationTitleAlternate | Cancer Metastasis Rev |
PublicationYear | 2010 |
Publisher | Springer US Springer Springer Nature B.V |
Publisher_xml | – name: Springer US – name: Springer – name: Springer Nature B.V |
References | DowsettMCuzickJWalesCForbesJMallonISalterJOn behalf of the ATAC Trialists’ GroupRisk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC studyCancer Research200969Suppl75sAbstract 53 ReganM. M.ColleoniM.Giobbie-HurderA.ThuerlimannB.MouridsenH.MauriacL.Adjusting for selective crossover in analyses of letrozole (Let) versus tamoxifen (Tam) in the BIG 1-98 trialCancer Research2009692416 RobinsJMFinkelsteinDMCorrecting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank testsBiometrics20005637797881:STN:280:DC%2BD3M%2Fms1yisg%3D%3D10.1111/j.0006-341X.2000.00779.x10985216 CoatesASKeshaviahAThurlimannBMouridsenHMauriacLForbesJFFive years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98Journal of Clinical Oncology20072554864921:CAS:528:DC%2BD2sXivF2mt7Y%3D10.1200/JCO.2006.08.861717200148 DoughtyJCA review of the BIG results: the Breast International Group 1-98 trial analysesBreast200817Suppl 1S9S1410.1016/S0960-9776(08)70003-118279765 BoccardoFRubagottiAPuntoniMGuglielminiPAmorosoDFiniASwitching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trialJournal of Clinical Oncology20052322513851471:CAS:528:DC%2BD2MXpsFWmtb4%3D10.1200/JCO.2005.04.12016009955 DixonJMRenshawLYoungOMurrayJMacaskillEJMcHughMLetrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancerJournal of Clinical Oncology20082610167116761:CAS:528:DC%2BD1cXltlWhsrk%3D10.1200/JCO.2007.13.927918375896 KaufmannMJonatWHilfrichJEidtmannHGademannGZunaIImproved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 StudyJournal of Clinical Oncology20072519266426701:CAS:528:DC%2BD2sXosValt7Y%3D10.1200/JCO.2006.08.805417563395 MamounasEPJeongJHWickerhamDLSmithREGanzPALandSRBenefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trialJournal of Clinical Oncology200826121965196711:CAS:528:DC%2BD1cXlvFaqs74%3D10.1200/JCO.2007.14.022818332472 HowellACuzickJBaumMBuzdarADowsettMForbesJFResults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancerLancet2005365945360621:STN:280:DC%2BD2M%2FhsVartA%3D%3D10.1016/S0140-6736(04)17666-615639680 American Cancer SocietyCancer Facts & Figures 20092009AtlantaAmerican Cancer Society MouridsenHGiobbie-HurderAGoldhirschAThürlimannBParidaensRSmithIBIG 1-98 Collaborative GroupLetrozole therapy alone or in sequence with tamoxifen in women with breast cancerThe New England Journal of Medicine2009361(8)7667761:CAS:528:DC%2BD1MXhtVWls7fM19692688 SchrothWGoetzMPHamannUFaschingPASchmidtMWinterSAssociation between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifenJournal of the American Medical Association200930213142914361:CAS:528:DC%2BD1MXht1CksrjO10.1001/jama.2009.142019809024 IngleJNDowsettMCuzickJDaviesCFor the Aromatase Inhibitors Overview Group (AIOG)Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategiesCancer Research200969Suppl 266sAbstract 12 PaikSShakSTangGKimCBakerJCroninMA multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancerThe New England Journal of Medicine20043512728171:CAS:528:DC%2BD2MXhslymsw%3D%3D10.1056/NEJMoa04158815591335 DowsettMCuzickJIngleJCoatesAForbesJBlissJMeta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus TamoxifenJournal of Clinical Oncology20102835095181:CAS:528:DC%2BC3cXivFartbk%3D10.1200/JCO.2009.23.127419949017 GossPEIngleJNMartinoSRobertNJMussHBPiccartMJRandomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor- positive breast cancer: updated findings from NCIC CTG MA.17Journal of the National Cancer Institute20059717126212711:CAS:528:DC%2BD2MXpvFKjsrY%3D10.1093/jnci/dji25016145047 MauriacLKeshaviahADebledMMouridsenHForbesJFThürlimannBBIG 1-98 Collaborative Group; International Breast Cancer Study GroupPredictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialAnnals of Oncology20071858598671:STN:280:DC%2BD2s3ns1Kksg%3D%3D10.1093/annonc/mdm00117301074 JonesSESeynaeveCHasenburgARaeDVannetzelJ-MParidaensRResults of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancerCancer Research200969Suppl66s GossPEIngleJNPaterJLMartinoSRobertNJMussHBLate extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifenJournal of Clinical Oncology20082612194819551:CAS:528:DC%2BD1cXlvFaqsrY%3D10.1200/JCO.2007.11.679818332475 MouridsenHTGiobbie-HurderAMauriacLParidaensRColleoniMThuerlimannBBIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancerCancer Research200969Suppl 266sAbstract 13 Del MastroLClavarezzaMVenturiniMReducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitorsCancer Treat Reviews200733868168710.1016/j.ctrv.2007.07.014 ReaDHasenburgASeynaeveCJonesSEVannetzelJMParidaensRFive years of exemestane as initial therapy compared to tamoxifen followed by exemestane for five years: the TEAM trial, a prospective, randomized, phase iii trial in postmenopausal women with hormone-sensitive early breast cancerCancer Research200969Suppls24 BlissJ. M.KilburnL. S.ColemanR. E.ForbesJ. F.CoatesA. S.JonesS. E.Disease related outcome with long term follow-up: an updated analysis of the Intergroup Exemestane Study (IES)Cancer Research2009692412 JakeszRGnantNGreilRTauschCSamoniggHKwasnyWThe benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5-year analysis of ABCSG Trial 8Breast Cancer Research and Treatment200594Suppl 1S10Abstract 13 GossPEIngleJNMartinoSRobertNJMussHBPiccartMJA randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerThe New England Journal of Medicine200334919179318021:CAS:528:DC%2BD3sXosl2gtbc%3D10.1056/NEJMoa03231214551341 MansellJMonypennyIJSkeneAIAbramPCarpenterRGattusoJMPatterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancerBreast Cancer Research and Treatment2009117191981:CAS:528:DC%2BD1MXpvFyitbg%3D10.1007/s10549-008-0291-z19112615 GlasAFlooreADelahayeLJWitteveenATPoverRCBakxNConverting a breast cancer microarray signature into a high-throughput diagnostic testBMC Genomics2006727810.1186/1471-2164-7-27817074082 Aubert, R. E., Stanek, E. J., Yao, J., Teagarden, J. R., Subar, M., Epstein, R. S., et al. (2009) Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Journal of Clinical Oncology 27(18 S). Abstract CRA508. van de VeldeCSeynaeveCHHasenburgAReaDVannetzelJMParidaensRResults of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancerEuropean Journal of Cancer Supplements200973110.1016/S1359-6349(09)72025-7Abstract 2BA LønningPEGeislerJAromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppressionThe Journal of Steroid Biochemistry and Molecular Biology20081083–519620210.1016/j.jsbmb.2007.09.01717996443 MonnierARefining the postmenopausal breast cancer treatment paradigm: the FACE trialExpert Review of Anticancer Therapy20066101355135910.1586/14737140.6.10.135517069521 BaumMBudzarAUCuzickJForbesJHoughtonJHKlijnJGATAC Trialists’ Group.ATAC Trialists’ GroupAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialLancet20023599324213121391:CAS:528:DC%2BD38XkslGhsLY%3D10.1016/S0140-6736(02)09088-812090977 GeislerJHelleHEkseDDuongNKEvansDBNordbøYLetrozole is superior to anastrozole suppressing breast cancer tissue and plasma estrogen levelsClinical Cancer Research20081419633063351:CAS:528:DC%2BD1cXhtF2nurbM10.1158/1078-0432.CCR-07-522118829517 JakeszRJonatWGnantMMittlboeckMGreilRTauschCABCSG and the GABGSwitching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trialLancet200536694844554621:CAS:528:DC%2BD2MXntVeisLw%3D10.1016/S0140-6736(05)67059-616084253 Goss, P. E., Ingle, J. N., Martino, S., Robert, N., Muss, H., Shepherd, L., et al. (2009) Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial. Cancer Research 69(24 Suppl):Abstract 13. LameratoLHavstadSGandhiSJonesDChlebowskiRBreast cancer recurrence and related mortality in US patients with early breast cancerJournal of Clinical Oncology20052316S62sAbstract 738 HoughtonJInitial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T) - data reported on behalf of the ATAC (‘Arimidex’, tamoxifen, alone or in Combination) Trialists’ groupAnnals of Oncology200617S LE Rutqvist (9248_CR30) 2007; 46 C Velde van de (9248_CR54) 2009; 7 A Monnier (9248_CR53) 2006; 6 RC Coombes (9248_CR14) 2007; 369 M Dowsett (9248_CR66) 2010; 28 9248_CR51 EP Mamounas (9248_CR46) 2001; 15 J Geisler (9248_CR37) 2008; 14 HF Kennecke (9248_CR64) 2007; 18 American Cancer Society (9248_CR1) 2009 R Jakesz (9248_CR45) 2007; 99 C Markopoulos (9248_CR68) 2009; 11 9248_CR56 EP Mamounas (9248_CR47) 2008; 26 D Rea (9248_CR40) 2009; 69 J Mansell (9248_CR4) 2009; 117 M Kaufmann (9248_CR55) 2007; 25 C Sotiriou (9248_CR21) 2009; 360 JM Dixon (9248_CR69) 2008; 26 R Jakesz (9248_CR42) 2005; 366 A Goldhirsch (9248_CR19) 2007; 18 L Mastro Del (9248_CR28) 2007; 33 9248_CR48 M Debled (9248_CR18) 2007; 109 PE Lønning (9248_CR35) 2008; 108 9248_CR49 R Jakesz (9248_CR58) 2005; 94 A Goldhirsch (9248_CR17) 2009; 20 JM Robins (9248_CR50) 2000; 56 EA Perez (9248_CR34) 2007; 18 JN Ingle (9248_CR65) 2009; 69 RC Coombes (9248_CR41) 2004; 350 R Jakesz (9248_CR59) 2009; 69 M Dowsett (9248_CR25) 2009; 69 A Buzdar (9248_CR36) 2006; 22 PE Goss (9248_CR62) 2008; 26 MG Lê (9248_CR10) 2002; 94 JA Sparano (9248_CR24) 2006; 7 J Houghton (9248_CR3) 2006; 17 S Paik (9248_CR23) 2006; 24 JF Forbes (9248_CR15) 2008; 9 R DeBoer (9248_CR52) 2006; 24 9248_CR8 PE Goss (9248_CR44) 2005; 97 B Fisher (9248_CR29) 2001; 93 9248_CR33 F Boccardo (9248_CR43) 2005; 23 M Baum (9248_CR38) 2002; 359 F Cardoso (9248_CR26) 2007; 1 PE Goss (9248_CR61) 2003; 349 MP Goetz (9248_CR31) 2007; 101 S Paik (9248_CR22) 2004; 351 W Schroth (9248_CR32) 2009; 302 A Glas (9248_CR9) 2006; 7 B Thurlimann (9248_CR11) 2005; 353 A Howell (9248_CR12) 2005; 365 9248_CR63 AS Coates (9248_CR13) 2007; 25 HT Mouridsen (9248_CR60) 2009; 69 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (9248_CR27) 2005; 365 H Mouridsen (9248_CR16) 2009; 361 L Lamerato (9248_CR5) 2005; 23 JC Doughty (9248_CR7) 2008; 17 T Saphner (9248_CR2) 1996; 14 9248_CR67 SY Jung (9248_CR20) 2009; 16 SE Jones (9248_CR39) 2009; 69 W Jonat (9248_CR57) 2006; 7 L Mauriac (9248_CR6) 2007; 18 |
References_xml | – volume: 14 start-page: 2738 issue: 10 year: 1996 ident: 9248_CR2 publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.1996.14.10.2738 contributor: fullname: T Saphner – volume: 93 start-page: 684 issue: 9 year: 2001 ident: 9248_CR29 publication-title: Journal of the National Cancer Institute doi: 10.1093/jnci/93.9.684 contributor: fullname: B Fisher – volume: 69 start-page: 75s issue: Suppl year: 2009 ident: 9248_CR25 publication-title: Cancer Research contributor: fullname: M Dowsett – volume: 1 start-page: 246 issue: 3 year: 2007 ident: 9248_CR26 publication-title: Molecular Oncology doi: 10.1016/j.molonc.2007.10.004 contributor: fullname: F Cardoso – ident: 9248_CR49 – volume: 353 start-page: 2747 issue: 26 year: 2005 ident: 9248_CR11 publication-title: The New England Journal of Medicine doi: 10.1056/NEJMoa052258 contributor: fullname: B Thurlimann – volume: 16 start-page: 1112 issue: 5 year: 2009 ident: 9248_CR20 publication-title: Annals of Surgical Oncology doi: 10.1245/s10434-009-0334-7 contributor: fullname: SY Jung – ident: 9248_CR51 doi: 10.1158/0008-5472.SABCS-09-16 – volume: 23 start-page: 62s issue: 16S year: 2005 ident: 9248_CR5 publication-title: Journal of Clinical Oncology contributor: fullname: L Lamerato – volume: 7 start-page: 278 year: 2006 ident: 9248_CR9 publication-title: BMC Genomics doi: 10.1186/1471-2164-7-278 contributor: fullname: A Glas – volume: 14 start-page: 6330 issue: 19 year: 2008 ident: 9248_CR37 publication-title: Clinical Cancer Research doi: 10.1158/1078-0432.CCR-07-5221 contributor: fullname: J Geisler – ident: 9248_CR67 doi: 10.1158/0008-5472.SABCS-09-4081 – volume: 365 start-page: 1687 issue: 9472 year: 2005 ident: 9248_CR27 publication-title: Lancet doi: 10.1016/S0140-6736(05)66544-0 contributor: fullname: Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) – volume: 69 start-page: s24 issue: Suppl year: 2009 ident: 9248_CR40 publication-title: Cancer Research contributor: fullname: D Rea – volume: 365 start-page: 60 issue: 9453 year: 2005 ident: 9248_CR12 publication-title: Lancet doi: 10.1016/S0140-6736(04)17666-6 contributor: fullname: A Howell – ident: 9248_CR8 – volume: 18 start-page: 1133 issue: 7 year: 2007 ident: 9248_CR19 publication-title: Annals of Oncology doi: 10.1093/annonc/mdm271 contributor: fullname: A Goldhirsch – volume: 69 start-page: 66s issue: Suppl year: 2009 ident: 9248_CR39 publication-title: Cancer Research contributor: fullname: SE Jones – volume: 23 start-page: 5138 issue: 22 year: 2005 ident: 9248_CR43 publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2005.04.120 contributor: fullname: F Boccardo – volume: 26 start-page: 1671 issue: 10 year: 2008 ident: 9248_CR69 publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2007.13.9279 contributor: fullname: JM Dixon – volume: 17 start-page: S9 issue: Suppl 1 year: 2008 ident: 9248_CR7 publication-title: Breast doi: 10.1016/S0960-9776(08)70003-1 contributor: fullname: JC Doughty – volume-title: Cancer Facts & Figures 2009 year: 2009 ident: 9248_CR1 contributor: fullname: American Cancer Society – volume: 109 start-page: 2197 issue: 11 year: 2007 ident: 9248_CR18 publication-title: Cancer doi: 10.1002/cncr.22667 contributor: fullname: M Debled – volume: 101 start-page: 113 issue: 1 year: 2007 ident: 9248_CR31 publication-title: Breast Cancer Research and Treatment doi: 10.1007/s10549-006-9428-0 contributor: fullname: MP Goetz – volume: 11 start-page: R35 issue: 3 year: 2009 ident: 9248_CR68 publication-title: Breast Cancer Research doi: 10.1186/bcr2320 contributor: fullname: C Markopoulos – volume: 350 start-page: 1081 issue: 11 year: 2004 ident: 9248_CR41 publication-title: The New England Journal of Medicine doi: 10.1056/NEJMoa040331 contributor: fullname: RC Coombes – volume: 366 start-page: 455 issue: 9484 year: 2005 ident: 9248_CR42 publication-title: Lancet doi: 10.1016/S0140-6736(05)67059-6 contributor: fullname: R Jakesz – volume: 7 start-page: 1 issue: 3 year: 2009 ident: 9248_CR54 publication-title: European Journal of Cancer Supplements doi: 10.1016/S1359-6349(09)72025-7 contributor: fullname: C Velde van de – volume: 17 start-page: 94 issue: Suppl. 9 year: 2006 ident: 9248_CR3 publication-title: Annals of Oncology contributor: fullname: J Houghton – volume: 369 start-page: 559 issue: 9561 year: 2007 ident: 9248_CR14 publication-title: Lancet doi: 10.1016/S0140-6736(07)60200-1 contributor: fullname: RC Coombes – volume: 15 start-page: 35 issue: 5 Suppl 7 year: 2001 ident: 9248_CR46 publication-title: Oncology contributor: fullname: EP Mamounas – volume: 26 start-page: 1948 issue: 12 year: 2008 ident: 9248_CR62 publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2007.11.6798 contributor: fullname: PE Goss – volume: 22 start-page: 1575 issue: 8 year: 2006 ident: 9248_CR36 publication-title: Current Medical Research and Opinion doi: 10.1185/030079906X120940 contributor: fullname: A Buzdar – volume: 28 start-page: 509 issue: 3 year: 2010 ident: 9248_CR66 publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2009.23.1274 contributor: fullname: M Dowsett – volume: 69 start-page: 66s issue: Suppl 2 year: 2009 ident: 9248_CR60 publication-title: Cancer Research contributor: fullname: HT Mouridsen – volume: 46 start-page: 133 issue: 2 year: 2007 ident: 9248_CR30 publication-title: Acta Oncology doi: 10.1080/02841860601034834 contributor: fullname: LE Rutqvist – volume: 302 start-page: 1429 issue: 13 year: 2009 ident: 9248_CR32 publication-title: Journal of the American Medical Association doi: 10.1001/jama.2009.1420 contributor: fullname: W Schroth – volume: 18 start-page: 26 issue: Suppl 8 year: 2007 ident: 9248_CR34 publication-title: Annals of Oncology doi: 10.1093/annonc/mdm263 contributor: fullname: EA Perez – volume: 94 start-page: S10 issue: Suppl 1 year: 2005 ident: 9248_CR58 publication-title: Breast Cancer Research and Treatment contributor: fullname: R Jakesz – volume: 24 start-page: 3726 issue: 23 year: 2006 ident: 9248_CR23 publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2005.04.7985 contributor: fullname: S Paik – ident: 9248_CR56 doi: 10.1158/0008-5472.SABCS-09-12 – volume: 25 start-page: 486 issue: 5 year: 2007 ident: 9248_CR13 publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2006.08.8617 contributor: fullname: AS Coates – volume: 99 start-page: 1845 issue: 24 year: 2007 ident: 9248_CR45 publication-title: Journal of the National Cancer Institute doi: 10.1093/jnci/djm246 contributor: fullname: R Jakesz – volume: 33 start-page: 681 issue: 8 year: 2007 ident: 9248_CR28 publication-title: Cancer Treat Reviews doi: 10.1016/j.ctrv.2007.07.014 contributor: fullname: L Mastro Del – volume: 24 start-page: 582s issue: 18S year: 2006 ident: 9248_CR52 publication-title: Journal of Clinical Oncology contributor: fullname: R DeBoer – ident: 9248_CR63 doi: 10.1158/0008-5472.SABCS-09-13 – volume: 117 start-page: 91 issue: 1 year: 2009 ident: 9248_CR4 publication-title: Breast Cancer Research and Treatment doi: 10.1007/s10549-008-0291-z contributor: fullname: J Mansell – volume: 360 start-page: 790 issue: 8 year: 2009 ident: 9248_CR21 publication-title: The New England Journal of Medicine doi: 10.1056/NEJMra0801289 contributor: fullname: C Sotiriou – volume: 7 start-page: 347 issue: 4 year: 2006 ident: 9248_CR24 publication-title: Clinical Breast Cancer doi: 10.3816/CBC.2006.n.051 contributor: fullname: JA Sparano – ident: 9248_CR48 – volume: 56 start-page: 779 issue: 3 year: 2000 ident: 9248_CR50 publication-title: Biometrics doi: 10.1111/j.0006-341X.2000.00779.x contributor: fullname: JM Robins – volume: 94 start-page: 2813 issue: 11 year: 2002 ident: 9248_CR10 publication-title: Cancer doi: 10.1002/cncr.10572 contributor: fullname: MG Lê – volume: 9 start-page: 45 issue: 1 year: 2008 ident: 9248_CR15 publication-title: Lancet Oncology doi: 10.1016/S1470-2045(07)70385-6 contributor: fullname: JF Forbes – ident: 9248_CR33 – volume: 108 start-page: 196 issue: 3–5 year: 2008 ident: 9248_CR35 publication-title: The Journal of Steroid Biochemistry and Molecular Biology doi: 10.1016/j.jsbmb.2007.09.017 contributor: fullname: PE Lønning – volume: 25 start-page: 2664 issue: 19 year: 2007 ident: 9248_CR55 publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2006.08.8054 contributor: fullname: M Kaufmann – volume: 69 start-page: 67s issue: Suppl year: 2009 ident: 9248_CR59 publication-title: Cancer Research contributor: fullname: R Jakesz – volume: 18 start-page: 859 issue: 5 year: 2007 ident: 9248_CR6 publication-title: Annals of Oncology doi: 10.1093/annonc/mdm001 contributor: fullname: L Mauriac – volume: 351 start-page: 2817 issue: 27 year: 2004 ident: 9248_CR22 publication-title: The New England Journal of Medicine doi: 10.1056/NEJMoa041588 contributor: fullname: S Paik – volume: 69 start-page: 66s issue: Suppl 2 year: 2009 ident: 9248_CR65 publication-title: Cancer Research contributor: fullname: JN Ingle – volume: 359 start-page: 2131 issue: 9324 year: 2002 ident: 9248_CR38 publication-title: Lancet doi: 10.1016/S0140-6736(02)09088-8 contributor: fullname: M Baum – volume: 97 start-page: 1262 issue: 17 year: 2005 ident: 9248_CR44 publication-title: Journal of the National Cancer Institute doi: 10.1093/jnci/dji250 contributor: fullname: PE Goss – volume: 18 start-page: 45 issue: 1 year: 2007 ident: 9248_CR64 publication-title: Annals of Oncology doi: 10.1093/annonc/mdl334 contributor: fullname: HF Kennecke – volume: 361 start-page: 766 issue: (8) year: 2009 ident: 9248_CR16 publication-title: The New England Journal of Medicine contributor: fullname: H Mouridsen – volume: 349 start-page: 1793 issue: 19 year: 2003 ident: 9248_CR61 publication-title: The New England Journal of Medicine doi: 10.1056/NEJMoa032312 contributor: fullname: PE Goss – volume: 20 start-page: 1319 issue: 8 year: 2009 ident: 9248_CR17 publication-title: Annals of Oncology doi: 10.1093/annonc/mdp322 contributor: fullname: A Goldhirsch – volume: 26 start-page: 1965 issue: 12 year: 2008 ident: 9248_CR47 publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2007.14.0228 contributor: fullname: EP Mamounas – volume: 6 start-page: 1355 issue: 10 year: 2006 ident: 9248_CR53 publication-title: Expert Review of Anticancer Therapy doi: 10.1586/14737140.6.10.1355 contributor: fullname: A Monnier – volume: 7 start-page: 991 issue: 12 year: 2006 ident: 9248_CR57 publication-title: The Lancet Oncology doi: 10.1016/S1470-2045(06)70948-2 contributor: fullname: W Jonat |
SSID | ssj0007379 |
Score | 2.1012585 |
SecondaryResourceType | review_article |
Snippet | Breast cancer is one of the leading causes of cancer-related deaths in women. Regardless of prognosis, all women with breast cancer are at risk for early... |
SourceID | pubmedcentral proquest gale crossref pubmed pascalfrancis springer |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 581 |
SubjectTerms | Adjuvant treatment Adjuvants Antineoplastic Agents, Hormonal - therapeutic use Aromatase Aromatase Inhibitors - therapeutic use Biological and medical sciences biomarkers Biomedical and Life Sciences Biomedicine Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cancer Cancer Research Clinical trials Female Gynecology. Andrology. Obstetrics Hormones Humans Mammary gland diseases Medical sciences Metastases Metastasis Mortality Neoplasm Metastasis Neoplasm Recurrence, Local - pathology Neoplasms, Hormone-Dependent - drug therapy Neoplasms, Hormone-Dependent - pathology Non-Thematic Review Oncology Patient outcomes Post-menopause Postmenopausal women Postmenopause Prognosis Reviews Subpopulations Surgery Survival Tamoxifen Treatment Outcome Tumors |
SummonAdditionalLinks | – databaseName: ProQuest Public Health Database dbid: 8C1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bi9UwEA66gggi3q27LhEEQQn2kkvrixwWl1U4PrmwbyVJU7YP23Y3PXDwJ-yv3pnejlXX56S5zST5pjP5hpB3IlGJi8uIGess4zrNmI51ykyhCp4VMpURPnBe_5Anp_z7mTgbY3P8GFY5nYn9QV00Fv-Rf0LSlgQv-C_tJcOkUehcHTNo3CX3Irzn8KH40S7CQ41Ue0jtraTIJqfm8HJOCIxaCxkYICnbLq6l8XB-2GoPC1UOGS7-BUH_jqT8w53a31LHj8mjEV7S1aAPT8gdVz8l99ejA_0ZuV5XdXVR_YKPqUNuY4qPWVrvqK4LeqG3U-EcgE6bTQcr5DytanoOCLepHfMY9o4HJW0bj9XA9N546NhgjHtHLerS1WfqkKBCW-wFl5c2JV19o32mEP-cnB5__Xl0wsZ0DMyCkdQxp0OTGWWNia3gBgwzHkdGWJmm0gmNvDCyjBznFhQjLLVVsS0Az1kBICwry-QF2athjK8IlWEpjEtN4aClRFgdOUBuwmluspKXYUA-TNLI24F1I9_xK6PochBdjqLLtwF5j_LKcUeCEGBWw8MC6Aq5rfKVitC3rLgMyP6ipm2ry_y30oNFKewzu_j4cKEP88DiJAEbkHNofVKQfDwIfD6rbUDezqXYMsa21a7ZeJwVmDkZQN-A0FvqKAnYCpBgFpCXg8btugcQjaQ-AVELXZwrIIH4sqSuznsi8RgzL2UwtI-T1u4Gfutyv_7vNPfJg3gO-Dkge93Vxr0B2NaZw35z3gA_7kMO priority: 102 providerName: ProQuest |
Title | Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials |
URI | https://link.springer.com/article/10.1007/s10555-010-9248-x https://www.ncbi.nlm.nih.gov/pubmed/20830503 https://www.proquest.com/docview/807430155 https://search.proquest.com/docview/1008829851 https://search.proquest.com/docview/760232839 https://pubmed.ncbi.nlm.nih.gov/PMC2962795 |
Volume | 29 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ba9RAFB60BRFEvJu2LiMIghLIZS6Jb3HZWpUtIi6sT2FmMqF5aBKbLJT-BH-152wua2r74EvyMCdzyTkz8x3OmW8IecNDGdog911trHGZimJXBSpydSYzFmciEj4ecF6eipMV-7Lm654sGs_CXIvf4xE3zjG9zHPBU4hcgIv7sAVLNOa5mI-Lruxp9ZDGWwoeDwHMm6qYbEH9QvygVg38lLy7zeImuPlv1uS10Ol2Rzp-RB72UJImne4fkzu2fELuLftg-VPye1mUxXlxBR9TizzGFA-u1I2lqszoubocCsdkc1ptWrBA29CipGeAZqvSug2muOOiSOuqQTFwszcNNKwxn72lBu3m4gO1SEahDLaC4QZa5TT5TLe3gjTPyOp48WN-4vZXL7gGHKLWtcrTsZZG68BwpsEJY4GvuRFRJCxXyAEjct8yZsAIvFwZGZgMsJvhALjiPA-fk70S-viSUOHlXNtIZxZqCrlRvgWUxq1iOs5Z7jnk3aCNtO4YNtIdlzKqLgXVpai69NIhb1FfKc4-UAKMqjtEAE0hj1WaSB_jyJIJhxxOJE1d_Er_Kj2alMKcMpOPZxN7GDsWhCH4e4xB7YOBpP2kb1LkFQoRgzrk9ViKNWMeW2mrTYOjApcmBpjrEHqLjBSAowD1xQ550VncrnkAzEjg4xA5scVRAMnCpyVlcbYlDQ_wlqUYuvZ-sNpdx2_93Qf_JX1I7gdjss8R2WsvNvYVQLZWz8hduZbwjOb-jOwnn35-XcD74-L02_fZdiLDcxUkfwDVCEJ_ |
link.rule.ids | 230,314,780,784,885,12056,12223,21388,27924,27925,31719,31720,33266,33267,33744,33745,41081,41120,41523,42150,42189,42592,43310,43579,43805,51576,52111,52234,73745,74014,74302 |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSICEEG9CSzESEhLIIg87TrigVUW1hW5PrdSbZTuOmkOTtMlKK34Cv5qZvJYA5WzHrxnb32TG3xDyTkQycmEeMGOdZVwnKdOhTpjJZMbTLE7iAB84r07i5Rn_di7Oh9icZgirHM_E7qDOKov_yD8haUuEF_yX-oph0ih0rg4ZNG6TO3DrS1Tq5GAb4SEHqj2k9paxSEenZv9yTgiMWvMZGCAJ28yupeFwflDrBhYq7zNc_AuC_h1J-Yc7tbulDh-RhwO8pIteHx6TW658Qu6uBgf6U_JzVZTFZfEDPqYOuY0pPmapG0d1mdFLvRkLpwB0Wq1bWCHX0KKkF4Bwq9KxBsPe8aCkddVgNTC91w10bDDGvaUWden6M3VIUKEt9oLLS6ucLo5olymkeUbODr-eHizZkI6BWTCSWua0b1IjrTGhFdyAYcbDwAgbJ0nshEZemDgPHOcWFMPPtZWhzQDPWQEgLM3z6DnZKWGMLwmN_VwYl5jMQUuRsDpwgNyE09ykOc99j3wYpaHqnnVDbfmVUXQKRKdQdGrjkfcoL4U7EoQAs-ofFkBXyG2lFjJA37LksUd2ZzVtXVyp30r3ZqWwz-zs4_2ZPkwDC6MIbEDOofVRQdRwEDRqUluPvJ1KsWWMbStdtW5wVmDmpAB9PUJvqCNjwFaABFOPvOg1bts9gGgk9fGInOniVAEJxOclZXHREYmHmHkphaF9HLV2O_Abl_vVf6f5htxbnq6O1fHRyfddcj-cgn_2yE57vXavAcK1Zr_bqL8AyrtGCg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1baxUxEA5aoQhSvNZta40gCEroXpK9-CKH6qFVT_HBQt9Ckk3oPnR3290DB3-Cv9qZs5fjqvV5srnNZPJlM_mGkNciSiIbuoBpYw3jKs2YClXKdJ7kPMvjNA7wgfPiLD45558vxEVPKdT0YZWDT1w76rwy-I_8CElbItzgj1wfFfHt4_xDfc0wgRRetPbZNO6Se5hkDmn00-NNtEfS0-4hzXcSi2y44Oxe0QmBEWw-g8NIylaTLap31A9q1cCkuS7bxb_g6N9RlX9cra53rPlDstNDTTrrbOMRuWPLx2R70V-mPyE_F0VZXBU_4GNqkeeY4sOWurFUlTm9UqtBOAaj02rZwmzZhhYlvQS0W5WWNRgCj06T1lWDxeAYvmygYY3x7i01aFc376lFsgplsBWcalo5Ojul66whzVNyPv_0_fiE9akZmIEDU8us8nWmE6N1aATXOOFhoIWJ0zS2QiFHTOwCy7kBI_GdMklocsB2RgAgy5yLnpGtEvr4nNDYd0LbVOcWaoqEUYEFFCes4jpz3PkeeTtoQ9YdA4fccC2j6iSoTqLq5Mojb1BfElcnKAFG1T0ygKaQ50rOkgDvmRMee2R_UtLUxbX8TXowkcKaM5OPDyf2MHYsjCI4D3IOtQ8GInun0MjRhD3yapRizRjnVtpq2eCo4MiTAQz2CL2lTBIDzgJUmHlkt7O4TfMAqJHgxyPJxBbHAkgmPpWUxeWaVDzELEwZdO3dYLWbjt863Xv_HeZLsg1rVH49PfuyT-6HYxzQAdlqb5b2BaC5Vh-u1-kv-ItKLw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Minimizing+early+relapse+and+maximizing+treatment+outcomes+in+hormone-sensitive+postmenopausal+breast+cancer%3A+efficacy+review+of+AI+trials&rft.jtitle=Cancer+and+metastasis+reviews&rft.au=Markopoulos%2C+Christos+J&rft.date=2010-12-01&rft.eissn=1573-7233&rft.volume=29&rft.issue=4&rft.spage=581&rft_id=info:doi/10.1007%2Fs10555-010-9248-x&rft_id=info%3Apmid%2F20830503&rft.externalDocID=20830503 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0167-7659&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0167-7659&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0167-7659&client=summon |